Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis

Gina M. Gallucci, Jocelyn Trottier, Christopher Hemme, David N. Assis, James L. Boyer, Olivier Barbier, Nisanne S. Ghonem – 26 August 2021 – Accumulation of cytotoxic bile acids (BAs) during cholestasis can result in liver failure. Glucuronidation, a phase II metabolism pathway responsible for BA detoxification, is regulated by peroxisome proliferator–activated receptor alpha (PPARα). This study investigates the efficacy of adjunct fenofibrate therapy to up‐regulate BA‐glucuronidation and reduce serum BA toxicity during cholestasis.

Light Chain Deposition Disease: An Unusual Cause of Portal Hypertension

Molly Delk Plummer, Fredric Regenstein – 26 August 2021 – Light chain deposition disease (LCDD) is a rare entity that is generally discovered in the setting of solid organ dysfunction. The monoclonal gammopathy leads to abnormal deposition of light chains in tissues, most often manifested by way of renal dysfunction. Other organ systems may also be affected, the liver being the second‐most common after the kidneys. Liver involvement rarely leads to clinically significant disease, with few case reports in the literature.

Subscribe to